Wednesday, February 19, 2014

Religare Health Trust - No surprises in 3Q (DBSV)

Religare Health Trust -
STI : 3,029.10
HOLD S$0.77
Price Target : 12-Month S$ 0.82 (Prev S$ 0.81)
No surprises in 3Q

• 3Q14 results as expected; DPU at 1.95 Scts
• Operations remained strong
• 1H15 distributions hedged at SGD/INR53.36
• Maintain HOLD, TP: S$0.82

3Q14 results within expectations. 3Q14 DPU was 2.14 Scts, which was in line with our expectations. Revenue improved by 1.3% q-o-q, but was 1.8% below its IPO projections due to a weaker INR. In INR terms, however, revenue was 11% higher than projected. Operating margins improved marginally to 59% in 3Q14 from 58.1% in 2Q14, arising from tighter cost control.

Operations remained strong. The average occupancy at its Clinical Establishments remained high at 78%, up from 3Q13’s 73%, but down from 2Q14’s 86%, as 2Q is a seasonally high quarter due to the summer months. Average Revenue per Operating Bed (ARPOB), however, saw an increase of 5.1% from 2Q14 mainly from price increases in Mulund CE and higher intensities at Kalyan CE.

Our View
1H15 distributions hedged at SGD/INR53.36. In Dec’13, RHT entered into forward contracts to hedge distributions for the 6- month period ending 30 Sep’14, at SGD/INR53.36. This is a step down from the SGD/INR47.79 rate for the preceding 6-month period ending 31 Mar’14. As a result a weaker INR, we project DPU to dip to 7.2 Scts in FY15F from 8.1 Scts in FY14F. We estimate that every 1% change in SGD/INR rate will impact DPU by 1% correspondingly.

Delivering on growth through acquisitions, expansions and Greenfield projects. RHT recently entered into a sale deed to acquire Mohali Clinical Establishment (CE) for S$58.2m (INR2,850m). This facility is an accredited hospital in North India and will help to enhance RHT’s distribution yield. To aid growth from FY16 onwards, RHT held a groundbreaking ceremony to develop a women’s hospital in Ludhiana and is looking to expand BG Road CE by another 200 beds.

Maintain HOLD, TP revised to S$0.82. We have factored in the recently announced proposed acquisition of the Mohali Clinical Establishment for INR2,850m. Our TP is adjusted up marginally to S$0.82, based on DDM (CoE: 12.2%, t=3%), to account for the acquisition. Maintain HOLD. A key upside risk to our recommendation is a significant strengthening of INR against SGD.

Source/Extract/Excerpts/来源/转贴/摘录: DBSV-Research,
Publish date: 13/02/14

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)

乔治·索罗斯(George Soros)



高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo

There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock